ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CELC Celcuity Inc

17.43
1.87 (12.02%)
Mar 01 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 392,465
Bid Price 15.16
Ask Price 21.37
News -
Day High 17.45

Low
8.389

52 Week Range

High
17.45

Day Low 15.46
Company Name Stock Ticker Symbol Market Type
Celcuity Inc CELC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.87 12.02% 17.43 17:30:00
Open Price Low Price High Price Close Price Prev Close
15.56 15.46 17.45 17.43 15.56
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,026 392,465 $ 16.00 $ 6,278,932 - 8.389 - 17.45
Last Trade Time Type Quantity Stock Price Currency
19:43:09 1 $ 18.50 USD

Celcuity Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
421.62M 24.20M - 0 -40.37M -1.67 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Celcuity News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CELC Message Board. Create One! See More Posts on CELC Message Board See More Message Board Posts

Historical CELC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.0517.4515.0515.55189,7432.3815.81%
1 Month15.1117.4513.7415.37137,6212.3215.35%
3 Months15.6217.4513.4814.84155,2891.8111.59%
6 Months9.5517.458.38913.52112,6647.8882.51%
1 Year11.8817.458.38912.2797,3715.5546.72%
3 Years14.2833.014.8116.63101,1523.1522.06%
5 Years22.6033.014.0316.1766,050-5.17-22.88%

Celcuity Description

Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR).

Your Recent History

Delayed Upgrade Clock